The maker of Shell ROTELLA® engine oil is leading the effort to have the U.S. White House formally recognize the pickup truck as the “Official Vehicle of the United States.” To pay homage to the substantial role pickup trucks play in shaping our nation and working their way into all parts of our society, Shell is honoring the vehicle by leading a national Shell ROTELLA® campaign, entitled “Pickup Pride” which may forever change the way Americans view the pickup truck.
“The campaign celebrates the achievements of hard-working Americans and highlights the pickup truck, which for almost a century, continues to support those who have given their blood, sweat, and tears to help build our country,” said Megan Pino, Global Brand Manager for Shell ROTELLA® engine oil. “The pickup truck exemplifies America’s resilience and the work it takes to continue to build our communities and support our farms, both which deserve to be recognized.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8157351-shell-rotella-pickup-truck-official-us-vehicle/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
A lot of people don’t even know they have hemorrhoids. The rectum is not an area you can readily see. Some times you don’t know you have hemorrhoids until you see blood in the toilet water after a bowel movement, when you start to have pain or discomfort in the rectum, or when you feel extra tissue around the rectum.
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
